Mingyue Rao

ORCID: 0000-0003-4448-7888
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hepatocellular Carcinoma Treatment and Prognosis
  • High Altitude and Hypoxia
  • Cancer Immunotherapy and Biomarkers
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Heart Rate Variability and Autonomic Control
  • Lung Cancer Research Studies
  • Head and Neck Cancer Studies
  • Heat shock proteins research
  • Metabolism, Diabetes, and Cancer
  • Liver Disease and Transplantation
  • Pancreatic and Hepatic Oncology Research
  • Hepatitis B Virus Studies
  • Ferroptosis and cancer prognosis
  • Cancer Research and Treatments
  • Cancer, Lipids, and Metabolism
  • Angiogenesis and VEGF in Cancer
  • Cancer, Hypoxia, and Metabolism
  • MicroRNA in disease regulation
  • Microbial Metabolites in Food Biotechnology
  • Cancer Cells and Metastasis
  • Effects of Environmental Stressors on Livestock
  • Bird parasitology and diseases
  • Biliary and Gastrointestinal Fistulas
  • Phagocytosis and Immune Regulation
  • Galectins and Cancer Biology

Chongqing Medical University
2011-2025

Affiliated Hospital of Southwest Medical University
2018-2025

First Affiliated Hospital of Xiamen University
2015-2024

Hebei Medical University
2020-2022

Second Hospital of Hebei Medical University
2020-2022

Macau University of Science and Technology
2018-2020

University of Macau
2019

Jawaharlal Nehru Centre for Advanced Scientific Research
2017

Army Medical University
2014-2015

Xinqiao Hospital
2014

Background Whether intensity-modulated radiotherapy (IMRT) can enhance the efficacy of programmed death (PD)-1 inhibitors combined with anti-angiogenic therapy for hepatocellular carcinoma (HCC) is unclear. Therefore, we conducted this multicenter retrospective study to investigate combination PD-1 and IMRT. Methods From April 2019 March 2022, a total 197 patients HCC [combination IMRT (triple group), 54; plus (control 143] were included in our study. Propensity score matching (PSM) was...

10.3389/fimmu.2022.972503 article EN cc-by Frontiers in Immunology 2022-09-23

A programmed death 1 (PD-1) inhibitor coupled with radiotherapy and antiangiogenic therapy is a potential therapeutic strategy for advanced hepatocellular carcinoma (HCC). We aimed to determine if circulating tumor cells (CTCs) positive death-ligand (PD-L1) could be employed as predictive biomarker in HCC patients receiving triple therapy.In this study, received PD-1 combination intensity-modulated (IMRT) therapy. Following IMRT, the was administrated once every 3 weeks, while drug given...

10.3389/fonc.2022.873830 article EN cc-by Frontiers in Oncology 2022-08-02

Abstract Background Although the diagnostic value of plasma heat-shock protein 90α (HSP90α) in hepatocellular carcinoma (HCC) has been previously reported, causal effect HSP90α levels on HCC prognosis remains largely unclear. To this extent, we sought to assess whether acts as a prognostic factor for patients. Methods A total 2150 patients were included retrospective study between August 2016 and July 2021. Plasma tested within week before treatment their association with was assessed....

10.1007/s12072-022-10391-y article EN cc-by Hepatology International 2022-08-16

The optimal locoregional treatment for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) is unclear. This study aimed to investigate the efficacy of Gamma knife radiosurgery (GKR) versus transcatheter arterial chemoembolization (TACE) in HCC PVTT.This retrospective included 544 PVTT (GKR, 202; TACE, 342). Propensity score matching (PSM) analysis identified 171 matched pairs patients. primary endpoint was overall survival (OS).Before PSM, GKR group exhibited...

10.1007/s12072-022-10339-2 article EN cc-by Hepatology International 2022-06-21

The purpose of this study was to investigate the efficacy and safety tislelizumab (monoclonal antibody) plus anlotinib (tyrosine kinase inhibitor) with or without radiotherapy in advanced hepatocellular carcinoma (HCC). Ninety patients HCC were divided into two groups: (TAR group) (TA based on treatment received. Radiotherapy performed three days during first cycle anlotinib. requirements dose95% ≥ 14.2-46 Gy for tumor volume. Efficacy evaluated according modified Response Evaluation...

10.1007/s12672-025-02171-5 article EN cc-by-nc-nd Discover Oncology 2025-03-25

// San-Gang Wu 1, * , Ming-Yue Rao 2, Juan Zhou 3, Qin Lin 1 Zi-Jing Wang Yong-Xiong Chen 4 Zhen-Yu He 5 Department of Radiation Oncology, Xiamen Cancer Center, the First Affiliated Hospital University, Xiamen, People's Republic China 2 Radiology, 3 Obstetrics and Gynecology, Eye Institute Fujian Provincial Key Laboratory Ophthalmology Visual Science, Medical College Sun Yat-sen University State Oncology in South China, Collaborative Innovation Center Medicine, Guangzhou, These authors have...

10.18632/oncotarget.5828 article EN Oncotarget 2015-10-19

Objective The purpose of this study was to observe left ventricular function during acute high-altitude exposure in a large group healthy young males. Methods A prospective trial conducted Szechwan and Tibet from June August, 2012. By Doppler echocardiography, examined 139 Chinese men at sea level; within 24 hours after arrival Lhasa, Tibet, 3700 m; on day 7 following an ascent Yangbajing 4400 m days acclimatization m. resting oxygen saturation (SaO2), heart rate (HR) blood pressure (BP)...

10.1371/journal.pone.0116936 article EN cc-by PLoS ONE 2015-01-28

Circular RNA (circRNA) is a noncoding that forms closed-loop structure, and its abnormal expression may cause disease. We aimed to find potential network for circRNA-related competitive endogenous (ceRNA) in atrial fibrillation (AF).The circRNA, miRNA, mRNA profiles the heart tissue from AF patients were retrieved Gene Expression Omnibus database analyzed comprehensively. Differentially expressed circRNAs (DEcircRNAs), differentially miRNAs (DEmiRNAs), mRNAs (DEmRNAs) identified, followed by...

10.1155/2020/8037273 article EN cc-by BioMed Research International 2020-09-29

Background In this retrospective study, we aimed to identify key risk factors and establish an interpretable model for HCC with a diameter ≥ 5 cm using Lasso regression effective stratification clinical decision-making. Methods 843 patients advanced hepatocellular carcinoma (HCC) tumor were included. Using screen multiple characteristic variables, cox proportional hazard random survival forest models (RSF) established. By comparing the area under curve (AUC), optimal was selected. The...

10.3389/fphar.2024.1452201 article EN cc-by Frontiers in Pharmacology 2024-09-19

To explore the myocardial protective effect of Neuregulin-4 (NRG-4) gene expression on spontaneous hypertension (SHR) rats and its mechanism through mediating activation ErbB signaling pathway, this study was conducted. For purpose, forty 24-week-old male SPF SHR were selected as experimental group, 10 age sex-matched Wistar Kyoto (WKY) control group. Cardiac tissues collected for hematoxylin-eosin (HE) staining, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling...

10.14715/cmb/2022.68.1.12 article EN cc-by Cellular and Molecular Biology 2022-05-22

To investigate the impact of response to induction chemotherapy (IC) on survival outcomes in patients with locally advanced nasopharyngeal carcinoma (LANPC) and evaluate efficacy adding nimotuzumab concurrent chemoradiotherapy (CCRT) based different responses IC. We retrospectively included stage III-IVA NPC who underwent IC without during CCRT. Statistical analysis chi-square test, propensity score matching, Kaplan-Meier analysis, Cox proportional hazards model. Among 383 identified...

10.1186/s12885-024-12731-7 article EN cc-by-nc-nd BMC Cancer 2024-08-02

Cholangiocarcinoma (CCA) is a rare disease with poor prognosis, and surgery remains the only curative treatment option. However, inappropriate for majority of patients CCA. Conversion therapy may provide opportunities surgical these patients. Herein, we describe patient intrahepatic CCA who was first treated albumin-bound paclitaxel, cisplatin, gemcitabine in combination camrelizumab. The then successfully underwent achieved pathological complete remission. This report can serve as reference...

10.3389/fimmu.2022.1051130 article EN cc-by Frontiers in Immunology 2022-12-23

Purpose To assess the causes of death (COD) and long-term survival after nasopharyngeal carcinoma (NPC) diagnosis. Methods Using linked data from Surveillance, Epidemiology, End Results program, patients with NPC diagnosed 1990 to 2010 followed up >5 years were identified. Chi-squared test, Kaplan–Meier method, Cox proportional hazard model used for analyses. Among 3,036 survivors, 1,432 survived >5–10 1,604 >10 years. The most common COD was primary (36.9%), by other...

10.3389/fpubh.2022.912843 article EN cc-by Frontiers in Public Health 2022-07-07

To investigate the prevalence and predictive factors of xerostomia during induction chemotherapy (IC) in patients with nasopharyngeal carcinoma (NPC).We prospectively enrolled NPC who received IC between October 2020 2021. The Visual Analogue Scale (VAS) Xerostomia Inventory (XI) were used to evaluate condition xerostomia. volume submandibular gland (SMG) was also calculated before after IC.Fifty-two this study. Of these patients, 32.7% (n = 17) experienced IC. There 32 (61.5%) suffered from...

10.1002/hed.27529 article EN Head & Neck 2023-09-26

Abstract Background The optimal management for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) is unclear. This study aimed to investigate the efficacy of Gamma knife radiosurgery (GKR) versus transcatheter arterial chemoembolization (TACE) in HCC PVTT. Methods retrospective included 572 PVTT (GKR, 207; TACE, 365). Propensity score matching (PSM) analysis identified 188 matched pairs patients. primary endpoint was overall survival (OS). Results Before PSM, GKR...

10.21203/rs.3.rs-1193272/v1 preprint EN cc-by Research Square (Research Square) 2022-01-03
Coming Soon ...